Six-gene scoring system could help predict AML survival
Researchers at the Centre for Genomic Regulation have identified a six-gene scoring system that helps predict survival outcomes for patients with acute myeloid leukaemia (AML). This method offers a more accurate and cost-effective prognostic tool than existing genetic profiles.
Why it matters
This discovery could lead to more personalized treatment plans and improved prognostic accuracy for patients suffering from blood cancer.
The activity of six different genes can help determine patient survival of acute myeloid leukaemia (AML), according to a study published in Science Advances . The findings by researchers at the Centre for Genomic Regulation (CRG) in Barcelona lay the foundations for new ways of predicting how patients will fare with a type of blood cancer that has widely variable outcomes from one patient to the next.
PHF19 on its own already tells us something about how patients will fare, but combining it with five other genes is a dramatic improvement which gives us more accurate information for AML prognosis
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in